Exhibit 16.1

 

June 2, 2023

 

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Ladies and Gentlemen:

 

We have read the statements made by Angion Biomedica Corp. included under Item 4.01(a) of its Current Report on Form 8-K dated June 2, 2023, to be filed with the Securities and Exchange Commission on June 2, 2023. We agree with the statements concerning our Firm contained therein.

 

Sincerely,

 

/s/ Moss Adams LLP

---